To add a bio or update investment portfolio click update information.
Northpond Ventures: Investment Portfolio & Startup News
Northpond Ventures
Investment Portfolio


OMass Therapeutics
15 Oct 2026
OMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
OMass Therapeutics is a biotechnology company developing small molecule therapeutics against highly validated target ecosystems in endocrinology and immunology. OMass Therapeutics develops OMS1620 for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome and advances an SLC15A4 inhibitor for lupus and related diseases.


Mestag Therapeutics
16 Mar 2026
Mestag Therapeutics secures £30m to advance fibroblast immunology cancer therapies
Mestag Therapeutics develops antibody treatments based on fibroblast immunology for cancer and inflammatory diseases. It is building therapies designed to direct and drive immune responses using fibroblast-immune biology.
Northpond Ventures
- 2(12 months)
- npv.vc
More venture news
- 17 Nov 2026

Isomorphic LabsIsomorphic Labs unlocks a £3.8bn Series C round led by Greenoaks and Sequoia Capital to design new medicines with AI
Series CLife Sciences - 11 Nov 2026

FractileFractile raises a £540m Series C from investors including Thrive and Founders Fund to build the chips that AI frontiers run on
Series CDeep Tech - 15 Oct 2026

OMass TherapeuticsOMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
Series CLife Sciences